CLINICAL DATA
+20 years of clinical validation.
200 research collaborations. 100s of publications
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Srkalovic, Patricia Robinson, Clodia Osipo, Kalyan Banda, Heather M. Kling, Midas M. Kuilman, Josien Haan, William Audeh, and FLEX Investigators Group Background: Invasive lobular carcinoma (ILC) comprises 10-15% of breast tumors and is the second most common histological type after Read More
Differential gene expression and clinical utility of MammaPrint and BluePrint in male breast cancer patients
PUBLICATION: SABCS 2020 AUTHORS: Jennifer A. Crozier, Julie Barone, Kalyan Banda, Beth Lesnikoski, Robert Maganini, Sami Diab, Ian Grady, Thomas Lomis, Charles Cox, Amy M. Truitt, Benjamin Nota, Andrea Menicucci9, Midas Kuilman, Erin Yoder, William Audeh, FLEX Investigators Background: Male breast cancer (MaBC) is rare, comprising <1% of all breast Read More
Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Michael Rotkis, Angela Mislowsky, Carrie Dul, Charles Nash, Bichlien Nguyen, Mary Murray, Paul Richards, Mark Gittleman13, Stephanie Akbari, Shiyu Wang, Andrea Menicucci, Erin B Yoder, Lisa Blumencranz, William Audeh, NBRST Investigators Group Background: The Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer
PUBLICATION:SABCS 2020AUTHORS:Laura Lee, Sami Diab, Julie Barone, Jennifer A. Crozier, Margret Chen, Rakshanda Layeequr Rahman, Robert Maganini, Douglas Marks, Amy M. Truitt, Lisa Blumencranz10, Erin Yoder10, William Audeh, Bastiaan van der Baan, FLEX Investigators GroupBackground:Genomic expression profiles have implications for the personalized treatment of breast cancer beyond clinical and pathological Read More
Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
PUBLICATION: SABCS 2020 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen L. Tedesco, Abirami Sivapiragasam, Jennifer A. Crozier, Apurva N. Shah, Yuan Yuan, Josien Haan, Andrea Menicucci, Michelle L. Bolner, Shiyu Wang, Lorenza Mittempergher, Erin Yoder, William Audeh9, FLEX Investigators' Group Background: Triple negative breast cancers (TNBC) are more aggressive, have Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Paul Baron, Peter Beitsch, Laura Lee, Michael Rotkis, Angela Mislowsky, Carrie Dul, Charles Nash, BichlienNguyen, Mary Murray, Paul Richards, Mark Gittleman, Stephanie Akbari, ShiyuWang, Erin B Yoder, Andrea Menicucci, Lisa Blumencranz, William Audeh, NBRST Investigators Group Background: MammaPrint (MP) Read More
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
PUBLICATION: SABCS 2020 AUTHORS:Iris Noordhoek, Esther Bastiaannet, Ersan Lujinovic, Laura Esserman, Jelle Wesseling, Astrid Scholten, Carolien Schroders, Sjoerd Elias, Nienke de Glas, Judith Kroep, Johanneke Portielje, Miranda Kleijn, Gerrit-Jan Liefers Introduction: Adjuvant therapy for hormone receptor positive (HR+) breast cancer (BC) is guided by clinicopathological risk factors, but these are Read More
